ClinicalTrials.gg
RecruitingNCT07695597Updated Jul 22, 2026

A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia

A Phase 2 interventional study of SYH2070 and Placebo in Mixed Hyperlipidemia, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 14 under way, 8 of them phase 3. Hyperlipoproteinemia Type II · China.

Planned enrollment
6th of 22
240 · median 142
Started
2026
with 5 others
Phase 2
3 of 24
1 open now
Primary completion
2027-04
later than 6 of 13 live
Registered
24th of 24
by date
Lead sponsor
5 of 24
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 6 of the 13 other live ones, and was the 24th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hyperlipoproteinemia Type II with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.

03

Conditions studied

  • Mixed Hyperlipidemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old, no gender limitation;
  2. 1.7 mmol/L (150 mg/dL) ≤ fasting TG ≤ 5.6 mmol/L (499 mg/dL) at screening;
  3. fasting LDL-C ≥ 2.6 mmol/L (100 mg/dL) at screening;
  4. Participants must have been continuously taking stable medium-intensity or higher statin drugs for at least 4 weeks, accompanied or not by cholesterol absorption inhibitors or fibrates, and maintain the same drug, dosage, frequency and brand throughout the trial period;
  5. Weight index range: 18.5 kg/m2 ≤ ≤ 40.0 kg/m2 at screening;
  6. Understand the trial procedures and methods, voluntarily participate in this trial and sign the ICF in person;
  7. Male participants with reproductive capacity and their partners who are reproductive-aged women must agree to use highly effective measures during the trial period and 24 weeks after the last administration of the trial drug; serum pregnancy tests before medication, serum or urine pregnancy tests during the trial period must be negative, and not be in the lactation period; participants are not allowed to donate sperm or eggs during the trial period and 24 weeks after the last administration of the trial drug.

Exclusion criteria

Exclusion Criteria:

  1. Genetic diagnosis or clinical diagnosis indicates homozygous familial hypercholesterolemia;
  2. During the screening or before randomization, there is -defined heart function grade Ⅲ-Ⅳ or known \< 30%;
  3. Within 3 months before the screening, there has been a new major cardiovascular adverse event, including acute coronary syndrome (such as myocardial infarction, unstable angina pectoris), cerebrovascular disease history (such as acute stroke or ), or acute pulmonary embolism;
  4. Within 3 months before the screening, there are arrhythmias, such as recurrent and symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular rate, atrial flutter with rapid ventricular rate, third-degree atrioventricular block, sinus arrest, etc.), drug or ablation-induced arrhythmias that cannot be controlled;
  5. Within 1 month before the screening, there is a history of percutaneous coronary intervention or peripheral artery revascularization surgery;
  6. At screening, there is poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
  7. Previously diseases that significantly affect lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, etc.;
  8. Previously diagnosed with type 1 diabetes, or type 2 diabetes > 8.5% at screening ;
  9. Within 1 year before the screening, there is a history of acute or chronic pancreatitis;
  10. Within 5 years before the screening, there is a history of malignant tumor (excluding well-treated basal cell skin cancer and cervical carcinoma in situ);
  11. Within 3 months before the screening, there is a history of major surgery (including coronary artery bypass grafting surgery) or planned major surgery during the trial;
  12. Plan to undergo percutaneous coronary intervention, coronary artery bypass grafting, carotid or peripheral artery revascularization, pacemaker implantation, cardiac resynchronization therapy, implantation of implantable cardioverter-defibrillator, etc. during the trial;
  13. At the time of screening or before randomization, there is an active infectious disease that the investigator deems not suitable for participation in the trial;
  14. Previously had a history of drug abuse, alcohol abuse, or drug addiction;
  15. Known to be allergic to the test drugs or have a severe allergic reaction to other small nucleic acid drugs;
  16. Within 6 months before the screening has used other ANGPTL3 inhibitor lipid-lowering drugs;
  17. Within 3 months before the screening has used PCSK9 monoclonal antibody lipid-lowering drugs;
  18. Within 1 year before the screening has used other siRNA lipid-lowering drugs;
  19. Within 2 months before the screening has received or plans to receive plasma exchange treatment;
  20. Within 3 months before the screening has used drugs with weight loss effects or undergone surgeries that cause unstable weight;
  21. Within 3 months before the screening has long-term continuous or repeated use of cyclosporine, systemic (excluding local use, such as intra-articular, nasal, inhalation, topical use, etc.; long-term continuous refers to ≥ 7 days; repeated refers to cumulative use ≥ 3 times);
  22. Within 3 months before the screening has participated in any clinical trial (excluding those who failed the screening), or is within 5 half-lives of the trial drug at the time of screening, with the longer time being the criterion;
  23. Any of the indicators meet the following criteria:

1) or aspartate aminotransferase or γ-glutamyl transferase exceeds 2.0 times the (ULN), or total exceeds 1.5 times of the ULN; 2) interval: for males, > 450 ms; for females, > 470 ms; 3) positive and HBV-DNA positive; or antibody positive and HCV RNA positive; or positive for antibody or anti- Treponema pallidum antibody; 4) Creatine kinase exceeds 3 times of the ULN; 5) Thyroid stimulating hormone is lower than the lower limit of normal or exceeds 1.5 times of the ULN (except for those who have been using thyroid hormone replacement therapy for 12 weeks or more before LDL-C testing in the screening period); 6) \< 30 mL/min/1.73m2 (calculated using the MDRD formula); 24. General criteria:

  1. Researchers evaluate those whose lifestyle has undergone significant changes within the previous 4 weeks, or those who cannot maintain it during the trial;
  2. Researchers determine that they are not suitable for subcutaneous injection;
  3. Pregnant or lactating women;
  4. Researchers judge that the participants have poor compliance or any factors that are not suitable for participating in this trial, including but not limited to participating in the trial would expose the participants to unacceptable risks or may interfere with the trial results.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    SYH2070, 150 mg

    Drug: SYH2070

  • Placebo comparator
    SYH2070, 150 mg placebo

    Drug: Placebo

  • Experimental
    SYH2070, 300 mg

    Drug: SYH2070

  • Placebo comparator
    SYH2070, 300 mg placebo

    Drug: Placebo

  • Experimental
    SYH2070, 400 mg

    Drug: SYH2070

  • Placebo comparator
    SYH2070, 400 mg placebo

    Drug: Placebo

Interventions

  • SYH2070 injection, 150 mg, 300 mg, 400 mg, SC, administration duration: 24 weeks

  • DrugPlacebo

    Placebo, SC, administration duration: 24 weeks

06

What researchers measure

Primary outcomes

  1. The percentage change in serum TG levels from baseline at week 24

    Time frame: Baseline through Week 24

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Sep 10, 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07695597
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jul 15, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Sep 10, 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYH2070

Start the discussion